<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01046123</url>
  </required_header>
  <id_info>
    <org_study_id>WHAM!</org_study_id>
    <nct_id>NCT01046123</nct_id>
  </id_info>
  <brief_title>Volumetric Modulated Arc Therapy (VMAT) for Brain Metastases</brief_title>
  <official_title>A Phase II Study of Whole Brain Radiotherapy With Simultaneous Integrated Boost Using Volumetric Modulated Arc Therapy for One to Ten Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiotherapy to the whole brain is standard treatment for cancer that has spread to the brain&#xD;
      (brain metastases) as it treats both the metastases that can be seen on scans and the brain&#xD;
      metastases that are too small to be seen on scans.&#xD;
&#xD;
      This study will use a novel radiotherapy technique, called volumetric modulated arc therapy&#xD;
      (VMAT), to treat patients with brain metastases. This technique allows delivery of both a&#xD;
      standard radiation dose to the whole brain as well as a higher radiation dose to the brain&#xD;
      metastases at the same time.&#xD;
&#xD;
      The study will assess the effectiveness of using VMAT in treating brain metastases, and&#xD;
      examine its potential side-effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II prospective clinical trial. Following registration, patients will be&#xD;
      required to undertake a baseline questionnaire assessment of daily living activities using&#xD;
      the Modified Barthel's index, as well as cognitive assessment using MMSE.&#xD;
&#xD;
      Patients will undergo MRI scan of the brain for radiotherapy planning purposes. During&#xD;
      radiotherapy planning and for each of the five radiotherapy fractions, patients will be&#xD;
      immobilised in a custom fitted stereotactic mask system, to minimise head movement. During&#xD;
      treatment, patients will have daily online setup corrections to ensure treatment accuracy.&#xD;
&#xD;
      Patients will be treated with WBRT/SIB using VMAT, delivering a total of 20 Gy in 5 fractions&#xD;
      to the whole brain and 50Gy in 5 fractions to the brain metastases, delivered once daily on&#xD;
      working days. Anti-nausea and anti-inflammatory medication will be prescribed to minimise&#xD;
      acute toxicity.&#xD;
&#xD;
      Following therapy completion, patients will be seen every 3 months for the 1st year, then&#xD;
      every 6 months thereafter. At each clinic visit, clinicians or study investigators will&#xD;
      monitor for toxicity from therapy, document neurologic symptoms and signs and performance&#xD;
      status as well as Modified Barthel's index and cognitive assessment.&#xD;
&#xD;
      Patients will have contrast-enhanced MRI brain at 3 months and 1 year, and contrast-enhanced&#xD;
      CT brain at 6 months and 9 months in the first year and every 6 months after the first year.&#xD;
      Serum creatinine levels will be done prior to each scan to ensure safety of intravenous&#xD;
      contrast administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3 month treatment response of metastases evaluated using contrast-enhanced MRI scan of brain</measure>
    <time_frame>3 months post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year local control of treated metastases evaluated with contrast-enhanced MRI scan of brain</measure>
    <time_frame>1 year post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year brain control of metastases evaluated with contrast-enhanced MRI scan of brain</measure>
    <time_frame>1 year post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median survival</measure>
    <time_frame>No time frame</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Both acute neurological toxicity (within 3 months of treatment) and late neurological toxicity (beyond 3 months of treatment</measure>
    <time_frame>3 months and beyond</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to decline in activities of daily living evaluated using the Modified Barthel index</measure>
    <time_frame>No time frame</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to decline in cognition evaluated with the Mini-mental state examination</measure>
    <time_frame>No time frame</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Whole brain radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy</intervention_name>
    <description>Patients will be treated with WBRT/SIB using VMAT, delivering a total of 20 Gy in 5 fractions to the whole brain and 50Gy in 5 fractions to the brain metastases, delivered once daily on working days.</description>
    <arm_group_label>Whole brain radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  pathologically confirmed solid malignancy diagnosed within the past 5 years (if the&#xD;
             original pathological cancer diagnosis is more than 5 years earlier, a biopsy to&#xD;
             confirm metastatic relapse within the past 5 years is required)&#xD;
&#xD;
          -  1-10 brain metastases&#xD;
&#xD;
          -  Maximum diameter of largest metastasis ≤ 3 cm&#xD;
&#xD;
          -  KPS ≥ 70&#xD;
&#xD;
          -  Patient is neurologically stable with or without corticosteroids&#xD;
&#xD;
          -  Extracranial disease well-controlled (6-month estimated median life expectancy).&#xD;
&#xD;
          -  Available for regular clinical and imaging follow up&#xD;
&#xD;
          -  Prior craniotomy permitted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Require craniotomy to relieve mass effect&#xD;
&#xD;
          -  Previous cranial radiotherapy&#xD;
&#xD;
          -  Metastatic germinoma, small cell carcinoma, multiple myeloma, lymphoma or leukaemia.&#xD;
&#xD;
          -  Chemotherapy administered within one week before radiotherapy or planned within one&#xD;
             week after radiotherapy.&#xD;
&#xD;
          -  Metastases within 0.7 cm of the optic chiasm, brainstem or optic nerves&#xD;
&#xD;
          -  Brainstem metastases&#xD;
&#xD;
          -  Systemic lupus erythematosis, scleroderma, or other connective tissue disorders not in&#xD;
             remission&#xD;
&#xD;
          -  Multiple sclerosis&#xD;
&#xD;
          -  Glomerular Filtration Rate &lt; 60 ml/minute&#xD;
&#xD;
          -  Non-small cell lung cancer with liver metastases&#xD;
&#xD;
          -  Bilirubin &gt; upper normal limit&#xD;
&#xD;
          -  AST or ALT &gt; 2X upper normal limit&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Summed volume of all metastasis PTVs &gt; 50 cm3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan M Nichol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BC Cancer Agency - Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 7, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>British Columbia Cancer Agency</investigator_affiliation>
    <investigator_full_name>Alan Nichol</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

